Kiniksa Pharmaceuticals International, plc
For the period ended Sep 30, 2025. Filed Oct 28, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 28, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
The following table shows the “Rule 10b5-1 trading arrangements” or “non-Rule 10b5-1 trading arrangements” (as such terms are defined under Item 408 of Regulation S-K) adopted, amended or terminated by our directors and officers during the three months ended September 30, 2025:
| E | |||||||
|---|---|---|---|---|---|---|---|
| · · · · Trading Arrangement · · | |||||||
| Name | Title | Action | Effective Date | Rule 10b5-1 | Non Rule 10b5-1 | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
| John Paolini | EVP, Chief Medical Officer | Adoption | July 30, 2025 | X | | October 31, 2026 | 111,867(2) |
| Mark Ragosa | EVP, Chief Financial Officer | Adoption | August 14, 2025 | X | | December 1, 2026 | 129,708(2)(3) |
| Barry Quart | Director | Adoption | September 11, 2025 | X | | December 15, 2026 | 58,889 |
| (1) | A trading arrangement may expire on an earlier date if all contemplated transactions are completed before such trading arrangement’s expiration date, upon termination by broker or the holder of the trading arrangement or as otherwise provided in the trading arrangement. |
| (2) | This figure includes a number of securities covered by a currently active plan and, therefore, may be less at the time that this plan goes into effect. |
| (3) | Includes Class A ordinary shares to be received upon the vesting of outstanding RSUs. The final amount of shares available for sale will be lower due to our net vesting policy for employee RSUs. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.